March 18 (Reuters) - Sarepta Therapeutics SRPT.O said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
Shares of the company fell nearly 24% to $77.29 in premarket trading.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
((Sriparna.Roy@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.